Get started
Author

Rafaela Pirolli

Observed names: Pirolli, Rafaela, R. Pirolli
Institution: AC Camargo Hospital
ORCID: 0000-0002-3668-2002
Observed ORCID: 0000-0002-3668-2002
OpenAlex ID: A5028292564
HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer
2021 · Luciana de Moura Leite, Marcelle Goldner Cesca, et al. · Breast Cancer Research and Treatment · 175
PDF
Immunotherapy as Single Treatment for Patients With NSCLC With Brain Metastases: A Systematic Review and Meta-Analysis—the META-L-BRAIN Study
2021 · Viviane Teixeira Loiola de Alencar, Marcos Pedro Guedes Camandaroba, et al. · Journal of Thoracic Oncology · 54
Anticoagulant-related nephropathy: systematic review and meta-analysis
2018 · Karolinny Borinelli de Aquino Moura, Paula Marques Prates Behrens, et al. · Clinical Kidney Journal · 50
PDF
Impact of BRCA1/2 Mutations on the Efficacy of Secondary Cytoreductive Surgery
2020 · Felipe Leonardo Estati, Rafaela Pirolli, et al. · Annals of Surgical Oncology · 10
HER2-low and gastric cancer: A prognostic biomarker?
2021 · Bruno Cezar de Mendonça Uchôa, Rafaela Pirolli, et al. · Journal of Clinical Oncology · 8
Development, validation and clinical application of a HPLC-FL method for CYP2D6 phenotyping in South Brazilian breast cancer patients
2014 · Marina Venzon Antunes, Dilana Elisabeth Staudt, et al. · Clinical Biochemistry · 7
Comparison of dose-dense vs. 3-weekly paclitaxel and carboplatin in the first-line treatment of ovarian cancer in a propensity score-matched cohort
2021 · Rafaela Pirolli, Viviane Teixeira Loiola de Alencar, et al. · BMC Cancer · 4
PDF
Influence of BRCA pathogenic variants in the benefit of secondary cytoreductive surgery.
2020 · Felipe Leonardo Estati, Viviane Alencar, et al. · Journal of Clinical Oncology · 2
P19.12 Immunotherapy as Single Treatment for Brain Metastases of Non-small cell Lung Cancer: A Systematic Review and Meta-Analysis
2021 · V. Alencar, M. Camandaroba, et al. · Journal of Thoracic Oncology · 1
PDF
256P Risk of CNS metastasis after neoadjuvant chemotherapy: Pathological complete response may not be enough
2020 · S.K. Loose, M.C. Tavares, et al. · Annals of Oncology · 1
PDF
Association of time interval from neoadjuvant chemotherapy to interval cytoreduction and interval cytoreduction to adjuvant chemotherapy with survival outcomes and risk of platinum resistance.
2020 · Viviane Alencar, Rafaela Pirolli, et al. · Journal of Clinical Oncology · 1
Risk of CNS relapse following pathological complete response to neoadjuvant chemotherapy in early breast cancer
2026 · Luciana de Moura Leite, Guilherme Rossato de Almeida, et al. · Breast Cancer Research and Treatment
PDF
Abstract PS4-08-27: Risk of CNS relapse following pathological complete response to neoadjuvant chemotherapy
2026 · L. M. Leite, G. R. de Almeida, et al. · Clinical Cancer Research
Abstract PO5-02-14: Clinical-pathological determinant factors to choose between four or six cycles of adjuvant chemotherapy with docetaxel/cyclophosphamide (TC) in a retrospective real-world cohort of HER2-negative breast cancer patients
2024 · Mila Kraychete, Marcelle Cesca, et al. · Cancer Research
Primary Prophylaxis With G-csf of Febrile Neutropenia in Breast Cancer Patients Treated With Adjuvant Docetaxel and Cyclophosphamide
2022 · Leonardo Gil Santana, Mila Meyer Kraychete, et al. · Brazilian Journal of Oncology
Abstract PS4-40: Her2 low status and response to neoadjuvant chemotherapy in Her2 negative early breast cancer
2021 · Bruna RaphaeliSilva Mattos, Marcelle Goldner Cesca, et al. · Cancer Research
Dose-dense carboplatin and paclitaxel versus three weekly regimen in the first-line treatment of ovarian carcinoma.
2020 · Rafaela Pirolli, Felipe Leonardo Estati, et al. · Journal of Clinical Oncology
Discordance between molecular subtyping from pre- and post-neoadjuvant chemotherapy (NACT) biopsy specimens in a Brazilian breast cancer cohort.
2020 · Monique Celeste Tavares, Luciana de Moura Leite, et al. · Journal of Clinical Oncology
Abstract P2-16-30: Neoadjuvant therapy outcomes in non metastatic invasive breast carcinomas - Results from a large Brazilian cohort
2020 · Monique Celeste Tavares, Marcelle G Cesca, et al. · Cancer Research
Outcomes of chemoradiotherapy for stage III non-small-cell lung cancer in Brazil.
2016 · Juliano Ce Coelho, Sabrina Richter Bedin, et al. · Journal of Clinical Oncology
Avaliação da idade como fator prognóstico em mulheres com menos de 40 anos com câncer de mama inicial
2014 · Pedro Emanuel Rubini Liedke, Fernanda Cano Casarotto, et al. · Lume (Universidade Federal do Rio Grande do Sul)
Impacto do uso de inibidores da CYP2D6 nos níveis plasmáticos de endoxifeno em pacientes com câncer de mama
2014 · Gilberto Schwartsmann, Rafael Linden, et al. · Lume (Universidade Federal do Rio Grande do Sul)
Desenvolvimento, validação e aplicação clínica de um método de fenotipagem da CYP2D6 em pacientes com câncer de mama em uso de tamoxifeno no sul do Brasil
2014 · Gustavo Gössling, Rafaela Pirolli, et al. · Lume (Universidade Federal do Rio Grande do Sul)
AB0210 Vitamin D and cardiovascular disease in systemic lupus erythematosus
2012 · O.A. Monticielo, J.A.B. Chies, et al. · Annals of the Rheumatic Diseases
RC 3095 : uma nova abordagem para a cura de tumores sólidos
2012 · Trasel, Andrea Ruschel, Anjos, Gabriel Marques dos, et al. · Lume (Universidade Federal do Rio Grande do Sul)
Works count: 27
Citation count: 313
H-index: 6
I10-index: 4
Year
Topic
Type